ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,869,191 | -44.3% | 1,105,309 | 0.0% | 2.34% | -32.6% |
| Q2 2023 | $10,533,595 | +68.3% | 1,105,309 | +94.2% | 3.47% | +34.7% |
| Q1 2023 | $6,259,451 | -25.7% | 569,041 | 0.0% | 2.58% | -29.6% |
| Q4 2022 | $8,421,807 | -22.6% | 569,041 | 0.0% | 3.66% | -7.9% |
| Q3 2022 | $10,874,000 | -10.3% | 569,041 | 0.0% | 3.97% | -34.9% |
| Q2 2022 | $12,126,000 | +10.6% | 569,041 | 0.0% | 6.11% | +17.8% |
| Q1 2022 | $10,960,000 | -7.1% | 569,041 | 0.0% | 5.19% | +5.1% |
| Q4 2021 | $11,802,000 | -13.2% | 569,041 | 0.0% | 4.94% | +2.7% |
| Q3 2021 | $13,594,000 | -12.5% | 569,041 | 0.0% | 4.80% | -21.5% |
| Q2 2021 | $15,529,000 | -5.7% | 569,041 | 0.0% | 6.12% | +15.9% |
| Q1 2021 | $16,462,000 | -12.9% | 569,041 | -15.3% | 5.28% | -15.2% |
| Q4 2020 | $18,895,000 | – | 671,716 | – | 6.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |